110 related articles for article (PubMed ID: 11205216)
21. Serum levels of soluble E-selectin in women with breast cancer.
Sheen-Chen SM; Eng HL; Huang CC; Chen WJ
Br J Surg; 2004 Dec; 91(12):1578-81. PubMed ID: 15386328
[TBL] [Abstract][Full Text] [Related]
22. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
[TBL] [Abstract][Full Text] [Related]
23. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
[TBL] [Abstract][Full Text] [Related]
24. Correlation between c-erbB2 expression, lymphovascular invasion and other biological and clinical prognostic factors and preoperative tumor markers in patients with early-stage and locally advanced breast cancer.
Aksu G; Duman C; Gurbuz Y; Ercin C; Canturk Z; Utkan Z; Dulger M
J BUON; 2011; 16(1):52-7. PubMed ID: 21674850
[TBL] [Abstract][Full Text] [Related]
25. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
26. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment values of serum CA 15-3 antigen related to prognostic factors in breast cancer patients.
Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
Neoplasma; 1996; 43(4):225-9. PubMed ID: 8931745
[TBL] [Abstract][Full Text] [Related]
28. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma.
Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Cancer Lett; 2005 Jan; 217(2):237-42. PubMed ID: 15617842
[TBL] [Abstract][Full Text] [Related]
29. [Occult multicentric breast cancer].
Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
[TBL] [Abstract][Full Text] [Related]
30. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity.
Hisai H; Kato J; Kobune M; Murakami T; Miyanishi K; Takahashi M; Yoshizaki N; Takimoto R; Terui T; Niitsu Y
Clin Cancer Res; 2003 Oct; 9(13):4852-9. PubMed ID: 14581357
[TBL] [Abstract][Full Text] [Related]
33. Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders.
Sasano H; Frost AR; Saitoh R; Matsunaga G; Nagura H; Krozowski ZS; Silverberg SG
Anticancer Res; 1997; 17(3C):2001-7. PubMed ID: 9216657
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
35. ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.
Meenakshi A; Kumar RS; Kumar NS
J Immunoassay Immunochem; 2002; 23(3):293-305. PubMed ID: 12227416
[TBL] [Abstract][Full Text] [Related]
36. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer.
Toi M; Taniguchi T; Ueno T; Asano M; Funata N; Sekiguchi K; Iwanari H; Tominaga T
Clin Cancer Res; 1998 Mar; 4(3):659-64. PubMed ID: 9533534
[TBL] [Abstract][Full Text] [Related]
37. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women.
Romppanen J; Keskikuru R; Kataja V; Eskelinen M; Kosma VM; Savolainen K; Uusitupa M; Mononen I
Br J Cancer; 1999 Mar; 79(9-10):1583-7. PubMed ID: 10188910
[TBL] [Abstract][Full Text] [Related]
38. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay.
Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994
[TBL] [Abstract][Full Text] [Related]
39. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
[TBL] [Abstract][Full Text] [Related]
40. The use of human monoclonal antibody to detect serum antigen in patients with breast cancer.
Strelkauskas AJ; Aldenderfer PH; Warner GA
Anticancer Res; 1989; 9(6):1863-8. PubMed ID: 2627133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
